» Articles » PMID: 18606138

Cthrc1 Selectively Activates the Planar Cell Polarity Pathway of Wnt Signaling by Stabilizing the Wnt-receptor Complex

Overview
Journal Dev Cell
Publisher Cell Press
Date 2008 Jul 9
PMID 18606138
Citations 157
Authors
Affiliations
Soon will be listed here.
Abstract

Vertebrate Wnt proteins activate several distinct pathways. Intrinsic differences among Wnt ligands and Frizzled (Fzd) receptors, and the availability of pathway-specific coreceptors, LRP5/6, and Ror2, affect pathway selection. Here, we show that a secreted glycoprotein, Cthrc1, is involved in selective activation of the planar cell polarity (PCP) pathway by Wnt proteins. Although Cthrc1 null mutant mice appeared normal, the introduction of a heterozygous mutation of a PCP gene, Vangl2, resulted in abnormalities characteristic of PCP mutants. In HEK293T cells, Cthrc1 activated the PCP pathway but suppressed the canonical pathway. Cell-surface-anchored Cthrc1 bound to Wnt proteins, Fzd proteins, and Ror2 and enhanced the interaction of Wnt proteins and Fzd/Ror2 by forming the Cthrc1-Wnt-Fzd/Ror2 complex. Consistent with this, Ror2 mutant mice also showed PCP-related abnormalities in the inner ear. These results suggest that Cthrc1 is a Wnt cofactor protein that selectively activates the Wnt/PCP pathway by stabilizing ligand-receptor interaction.

Citing Articles

Expression Results in Secretion-Mediated, SOX9-Dependent Suppression of Adipogenesis: Implications for the Regulatory Role of Newly Identified CTHRC1/PDGFR-Alpha Stromal Cells of Adipose.

Siviski M, Bercovitch R, Pyburn K, Potts C, Pande S, Gartner C Int J Mol Sci. 2025; 26(5).

PMID: 40076432 PMC: 11898434. DOI: 10.3390/ijms26051804.


Non-canonical Wnt signaling pathway activated NFATC3 promotes GDF15 expression in MASH: prospective analyses of UK biobank proteomic data.

Wang H, Xu X, Shi L, Huang C, Sun Y, You H Hepatol Int. 2025; .

PMID: 39836348 DOI: 10.1007/s12072-024-10775-2.


Non-canonical Wnt signaling triggered by WNT2B drives adrenal aldosterone production.

Borges K, Little 3rd D, de Almeida Magalhaes T, Ribeiro C, Dumontet T, Lapensee C bioRxiv. 2024; .

PMID: 39229119 PMC: 11370552. DOI: 10.1101/2024.08.23.609423.


Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.

Li L, Huang W, Ren X, Wang Z, Ding K, Zhao L Sci China Life Sci. 2024; 67(12):2603-2616.

PMID: 39145866 DOI: 10.1007/s11427-024-2685-9.


CTHRC1: An Emerging Hallmark of Pathogenic Fibroblasts in Lung Fibrosis.

Mukhatayev Z, Adilbayeva A, Kunz J Cells. 2024; 13(11.

PMID: 38891078 PMC: 11171484. DOI: 10.3390/cells13110946.